Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5975
    -0.0001 (-0.01%)
     
  • NZD/EUR

    0.5541
    +0.0008 (+0.14%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,327.50
    +159.43 (+0.40%)
     
  • NZD/JPY

    90.3950
    +0.0020 (+0.00%)
     

Teva Is Implementing This Strategy as Part of Its Restructuring

Teva Is Implementing This Strategy as Part of Its Restructuring

In December 2017, Teva Pharmaceutical (TEVA) laid down its restructuring plan, which included R&D (research and development) optimization involving the consolidation of its R&D sites while maintaining a robust R&D portfolio. For more details, read What’s Teva Pharmaceutical’s Research and Development Strategy? Since Teva laid out its restructuring plans, it has cut down 25 of its specialty area projects, representing ~27% of its R&D programs.